EA201791350A1 - Радиофармацевтические комплексы - Google Patents
Радиофармацевтические комплексыInfo
- Publication number
- EA201791350A1 EA201791350A1 EA201791350A EA201791350A EA201791350A1 EA 201791350 A1 EA201791350 A1 EA 201791350A1 EA 201791350 A EA201791350 A EA 201791350A EA 201791350 A EA201791350 A EA 201791350A EA 201791350 A1 EA201791350 A1 EA 201791350A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tissue
- chelator
- targeted
- thorium
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Изобретение касается способа образования комплекса тория, нацеленного на ткань, при этом указанный способ включает следующие этапы: а) образование октадентатного хелатора, содержащего четыре гидроксипиридиноновых фрагмента (НОРО), замещенных в N-положении C-C-алкильной группой, и соединительный фрагмент, заканчивающийся группой карбоновой кислоты; b) соединение указанного октадентатного хелатора по меньшей мере с одним нацеленным на ткань пептидом или белком, содержащим по меньшей мере один аминный фрагмент, с помощью по меньшей мере одного реагента, связывающего амиды, в результате чего получают нацеленный на ткань хелатор; и с) контактирование указанного нацеленного на ткань хелатора с водным раствором, содержащим ион по меньшей мере одного изотопа тория, излучающего альфа-частицы. Кроме того, настоящее изобретение касается способа лечения неопластического или гиперпластического заболевания, включающего введение такого комплекса тория, нацеленного на ткань, а также комплекса и соответствующих фармацевтических препаративных форм.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201422512 | 2014-12-17 | ||
PCT/EP2015/079773 WO2016096843A1 (en) | 2014-12-17 | 2015-12-15 | Radio-pharmaceutical complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791350A1 true EA201791350A1 (ru) | 2017-12-29 |
EA201791350A9 EA201791350A9 (ru) | 2020-02-11 |
Family
ID=54884033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791350A EA201791350A9 (ru) | 2014-12-17 | 2015-12-15 | Радиофармацевтические комплексы |
Country Status (30)
Country | Link |
---|---|
US (2) | US20170340759A1 (ru) |
EP (1) | EP3233137A1 (ru) |
JP (2) | JP6821569B2 (ru) |
KR (1) | KR20170094223A (ru) |
CN (1) | CN107278155B (ru) |
AR (1) | AR103063A1 (ru) |
AU (2) | AU2015367722A1 (ru) |
BR (1) | BR112017012841A2 (ru) |
CA (1) | CA2970841A1 (ru) |
CL (1) | CL2017001592A1 (ru) |
CO (1) | CO2017005975A2 (ru) |
CR (1) | CR20170256A (ru) |
CU (1) | CU24493B1 (ru) |
DO (1) | DOP2017000143A (ru) |
EA (1) | EA201791350A9 (ru) |
EC (1) | ECSP17038089A (ru) |
IL (1) | IL252244B (ru) |
JO (1) | JOP20150319B1 (ru) |
MA (1) | MA41176A (ru) |
MX (1) | MX2017008093A (ru) |
MY (1) | MY194190A (ru) |
NI (1) | NI201700076A (ru) |
PE (2) | PE20171181A1 (ru) |
PH (1) | PH12017501125A1 (ru) |
SG (1) | SG11201704917XA (ru) |
TN (1) | TN2017000255A1 (ru) |
TW (1) | TWI654179B (ru) |
UA (1) | UA125369C2 (ru) |
UY (1) | UY36453A (ru) |
WO (1) | WO2016096843A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108778347A (zh) * | 2016-03-24 | 2018-11-09 | 拜耳制药股份公司 | 放射性药物配合物 |
BR112018075554A2 (pt) * | 2016-06-10 | 2019-10-01 | Bayer As | complexos radiofarmacêuticos |
WO2018153975A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
JP2020515596A (ja) * | 2017-03-30 | 2020-05-28 | コーネル ユニバーシティー | α線放出放射線核種の大環状錯体およびがんの標的放射線療法におけるそれらの使用 |
CA3110754A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
US20220125960A1 (en) | 2019-02-21 | 2022-04-28 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
EP3927339A1 (en) | 2019-02-22 | 2021-12-29 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
AR119479A1 (es) | 2019-07-25 | 2021-12-22 | Bayer As | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer |
TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
CN116745323A (zh) | 2021-01-22 | 2023-09-12 | 拜耳股份有限公司 | Lrrc15抗体及其缀合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008085064A2 (en) * | 2007-01-11 | 2008-07-17 | Ge Healthcare As | Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents |
GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2015
- 2015-12-14 MA MA041176A patent/MA41176A/fr unknown
- 2015-12-15 MX MX2017008093A patent/MX2017008093A/es unknown
- 2015-12-15 UA UAA201707516A patent/UA125369C2/uk unknown
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/en active Pending
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/en active Application Filing
- 2015-12-15 EA EA201791350A patent/EA201791350A9/ru unknown
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 CU CU2017000082A patent/CU24493B1/es unknown
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/zh active Active
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/es unknown
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/ko not_active Application Discontinuation
- 2015-12-15 CA CA2970841A patent/CA2970841A1/en active Pending
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/es unknown
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/pt not_active Application Discontinuation
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 CR CR20170256A patent/CR20170256A/es unknown
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/ja active Active
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/ar active
- 2015-12-17 AR ARP150104130A patent/AR103063A1/es unknown
- 2015-12-17 UY UY0001036453A patent/UY36453A/es not_active Application Discontinuation
- 2015-12-17 TW TW104142567A patent/TWI654179B/zh active
-
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/es unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/es unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/es unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/es unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/es unknown
-
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/ja active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791350A1 (ru) | Радиофармацевтические комплексы | |
EA201892814A1 (ru) | Радиофармацевтические комплексы | |
GT201400253A (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
EA201890796A1 (ru) | Новое антитело к мезотелину и содержащая его композиция | |
EA201890039A1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения | |
EA201500923A1 (ru) | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с | |
EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
EA201891291A1 (ru) | Мультиспецифические антитела | |
EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
UA117364C2 (uk) | Похідні аматоксину | |
EA201990071A1 (ru) | Композиция пептидной вакцины | |
EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
EA201490735A1 (ru) | Лечение дегенеративного заболевания сустава | |
EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
EA201890282A1 (ru) | Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты | |
BR112016017997A2 (pt) | Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos | |
EA201790773A1 (ru) | Композиции и способы для ингибирования биологической активности растворимых биомолекул | |
EA201891141A1 (ru) | Новые антиангиогенные слитые полипептиды | |
CY1125448T1 (el) | Μεθοδοι για την ενισχυμενη αφαιρεση προσμειξεων κατα τη διαρκεια χρωματογραφιας πρωτεϊνης α | |
EA201891639A1 (ru) | Аминокислотные и пептидные конъюгаты и способ конъюгации | |
CL2012000938A1 (es) | Aptamero que se une al virus de la septicemia viral hemorrágica (vhsn); adn que codifica el aptamero, vector de expresión; transformante que se obtiene al introducir dicho vector; método para extraer el vhsv; composicion farmaceutica para tratar o prevenir la vhs; estuche de detección del vhsv. | |
EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |